Observed Signal · Sep 24, 2026 · Clinical Data Presentation · Source: PR Newswire: Advertising & Marketing · Impact: 1/5 · Sentiment: Neutral
REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy
REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.
Clinical trial results for a gene therapy are specific to the biotech industry and not directly relevant to AdTech, MarTech, or digital advertising. While it may have indirect implications for healthcare advertising, it does not impact the advertising technology ecosystem directly.
Track AbbVie Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- 60% of Dose Level 3 participants (n=6/10) achieved >2-step DRSS improvement at 3 years post-treatment.
- No vision-threatening events or additional treatment for diabetic retinopathy observed in these participants.
- No intraocular inflammation (IOI) observed with short-course prophylactic topical steroids through three years.
- Data presented at Retina Society 59th Annual Scientific Meeting in Los Angeles.
- Sura-vec is being evaluated in the Phase IIb/III NAAVIGATE trial for NPDR.
Connected Companies & Entities
1 Entity mapped“surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie....”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ and prophylactic strategies.
Insilico Doses First Patient in World's First Generative AI-Driven Phase III Trial
Insilico Medicine announced it has dosed the first patient in GENESIS-IPF-3, the world's first Phase III clinical trial of a generative AI-driven innovative drug. The trial evaluates Rentosertib (ISM001-055) for idiopathic pulmonary fibrosis (IPF) at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital. Rentosertib targets TNIK, a novel AI-discovered target, and showed promising Phase IIa results. The Phase III study is a 52-week, randomized, double-blind, placebo-controlled trial across 47 centers in China, enrolling 320 patients. Insilico also reported strong financial performance, with $106M revenue in H1 2026 and over $7.3B in new contract value, highlighting its AI-driven drug discovery platform's commercial viability.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.